BioSpace News Archive

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2020 financial results prior to market open on Monday, May 11, 2020. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results. The conferenc

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the nomination of biotech industry veteran Terri Shoemaker to the Company’s Board of Directors. Ms. Shoemaker brings more than 30 years of extensive commercial and leadership experience to Onconova. Ms. Shoemaker will j

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most, today announced the pre-IND submission to the U.S. Food and Drug Administration (

Data presented demonstrates that patients with a past medical history of pneumonitis had a higher incidence of treatment associated pneumonitis in both clinical trial and real-world data AACR Virtual Annual Meeting Plenary Session April 27, 2020 at 4:00 PM EDT SAN FRANCISCO, April 27, 2020 (GLOBE NEWSWIRE) -- Syapse announced that research results stemming from its Research Collaboration Agreement with the U.S. Food and Drug Administration (FDA) will be presented today at the Clinic

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, plans to report first quarter 2020 financial results on Thursday, May 7, 2020, after the close of U.S. markets. Following the announcement, the company will host a conference call beginning at 5:00 p.m. ET to di

Mateon Therapeutics Inc. (OTCQB:MATN) announced today it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to study its investigational drug, OT-101, for the treatment of COVID-19 pandemic. The proposed randomized, double-blind, placebo-controlled Phase 2 study is intended to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with COVID-19 and pneumonia in th

Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that it has entered into a private Securities Purchase Agreement with a U.S.-based, healthcare-focused institutional investor

The antimicrobials Cefiderocol and imipenem/relebactam are now available on the U.S. Food and Drug Administration (FDA) approved microbroth dilution susceptibility plates, expanding testing options for microbiology laboratories, and providing the quantitative susceptibility results clinicians need to make treatment decisions for serious Gram-negative infections.

INOVIO (NASDAQ:INO) announced today that first quarter 2020 financial results will be released after the market close on May 11, 2020 . Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update, including the company’s

Gilson and QIAGEN have entered into a strategic partnership that will provide researchers the ability to limit operator-dependent variation in their manual nucleic acid extraction results and improve the traceability of their workflows. This agreement brings together two influential leaders in the life science industries: Gilson, a global manufacturer of sample preparation technology, and QIAGEN, a leading global p